CAS 571190-30-2

Palbociclib

Description:

Palbociclib is an oral medication classified as a selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), primarily used in the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Its chemical formula is C24H29N5O2, and it features a complex structure that includes a pyridazine ring, which is crucial for its biological activity. Palbociclib works by disrupting the cell cycle, specifically inhibiting the transition from the G1 phase to the S phase, thereby preventing cancer cell proliferation. The substance is typically administered in combination with aromatase inhibitors or estrogen receptor antagonists to enhance therapeutic efficacy. Palbociclib is characterized by its moderate solubility in organic solvents and relatively low solubility in water, which can influence its bioavailability. Its pharmacokinetics indicate a significant first-pass metabolism, primarily by the liver, and it has a half-life that supports once-daily dosing. As with many targeted therapies, monitoring for side effects such as neutropenia is essential during treatment.

Formula: C₂₄H₂₉N₇O₂

InChI: InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)

InChI key: InChIKey=AHJRHEGDXFFMBM-UHFFFAOYSA-N

SMILES: O=C1N(C=2C(C(C)=C1C(C)=O)=CN=C(NC3=CC=C(C=N3)N4CCNCC4)N2)C5CCCC5

Synonyms:

• 6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)pyrido[2,3-d]pyridin-7(8H)-one
• 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(1-piperazinyl)-2-pyridinyl]amino]pyrido[2,3-d]pyrimidin-7(8H)-one
• 6-Acetyl-8-cyclopentyl-5-methyl-2-[[5-(piperazin-1-yl)pyridin-2-yl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one
• 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-ylpyridin-2-ylamino)-8H-pyrido(2,3-d)pyrimidin-7-one
• Ibrance
• Otava-Bb 1115529
• Palbociclib
• Palbociclib base
• Palbocyclib
• Pd 332991
• Pd 991
• Pd-0332991
• Pd0332991

Palbociclib

CAS: 571190-30-2

Palbociclib

Purity: ≥98%

Molecular weight: 447.53g/mol

Ref: 54-BUP14421

Palbociclib

CAS: 571190-30-2

Formula: C₂₄H₂₉N₇O₂

Color and Shape: Yellow Solid

Molecular weight: 447.54

Ref: 4Z-P-196001

Palbociclib

CAS: 571190-30-2

Formula: C₂₄H₂₉N₇O₂

Purity: >97.0%(T)(HPLC)

Color and Shape: White to Yellow to Yellow green powder to crystal

Molecular weight: 447.54

Ref: 3B-P3315

Palbociclib

CAS: 571190-30-2

Color and Shape: Neat

Ref: 86-MM3729.00

Palbociclib

CAS: 571190-30-2

Formula: C₂₄H₂₉N₇O₂

Purity: (TLC) ≥ 98.0%

Color and Shape: Yellow powder

Molecular weight: 447.53

Ref: 7W-GX0330

Palbociclib

CAS: 571190-30-2

Palbociclib is an oral CDK4/6 inhibitor, halts Rb phosphorylation, arrests cell cycle, and curbs tumor growth.

Formula: C₂₄H₂₉N₇O₂

Purity: 98% - 99.9%

Color and Shape: Solid

Molecular weight: 447.53

Ref: TM-T1785

Palbociclib Sulfate Sodium Salt

Controlled Product

CAS: 571190-30-2

Applications Palbociclib Sulfate is a derivative of Palbociclib (P139900) which is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Formula: C₂₄H₂₈N₇NaO₅S

Color and Shape: Neat

Molecular weight: 549.58

Ref: TR-P139905

Palbociclib-d4

Controlled Product

CAS: 571190-30-2

Applications Palbociclib-d4 is an isotope labelled compound of Palbociclib (P139900). Palbociclib (P139900) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Formula: C₂₄H₂₅D₄N₇O₂

Color and Shape: Light Yellow

Molecular weight: 451.56

Ref: TR-P139901

Palbociclib - Bio-X ™

CAS: 571190-30-2

This product is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready-to-use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.

Formula: C₂₄H₂₉N₇O₂

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 447.53 g/mol

Ref: 3D-BP166224

Palbociclib

CAS: 571190-30-2

Selective and potent inhibitor of cyclin-dependent kinases CDK4 and CDK6. It blocks cell cycle progression from phase G1 into S by inhibiting CDK4/6-dependent retinoblastoma (RB) phosphorylation. It has been used for the treatment of HER2 negative, estrogen receptor (ER) positive metastatic breast cancer.

Formula: C₂₄H₂₉N₇O₂

Purity: Min. 95%

Color and Shape: Powder

Molecular weight: 447.53 g/mol

Ref: 3D-FA65120

Palbociclib-d4 Hydrochloride

Controlled Product

CAS: 571190-30-2

Applications Palbociclib-d4 Hydrochloride is an intermediate in synthesizing Palbociclib-d4 (P139901), an isotope labelled compound of Palbociclib (P139900). Palbociclib (P139900) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Formula: C₂₅H₂₇D₄N₇O₂·HCl

Color and Shape: Neat

Molecular weight: 465.58 + (36.46)

Ref: TR-P139937

Palbociclib N-β-D-Glucuronide Sodium Salt (Technical Grade, ~65%)

Controlled Product

CAS: 571190-30-2

Applications Palbociclib N-β-D-Glucuronide is a derivative of Palbociclib (P139900) which is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009)

Formula: C₃₀H₃₆N₇NaO₈

Purity: ~65%

Color and Shape: Neat

Molecular weight: 645.64

Ref: TR-P139910

Palbociclib

CAS: 571190-30-2

Purity: 95%

Color and Shape: Solid

Molecular weight: 447.5429993

Ref: 10-F794410

Palbociclib

CAS: 571190-30-2

Applications Palbociclib (also known as compound number PD-0332991) is an experimental drug for the treatment of breast cancer being developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6.
References Finn, R., et al.: Breast Cancer Res., 11, 5 (2009);

Formula: C₂₄H₂₉N₇O₂

Color and Shape: Neat

Molecular weight: 447.53

Ref: TR-P139900

Maillard Product

Controlled Product

CAS: 571190-30-2

Formula: C₃₆H₄₉N₇O₁₂

Color and Shape: Neat

Molecular weight: 771.814

Ref: TR-M411860

6-Acetyl-8-cyclopentyl-5-methyl-2-((5-(1-piperazinyl)-2-pyridinyl)amino)pyrido[2,3-d]pyridin-7(8H)-one

CAS: 571190-30-2

Formula: C₂₄H₂₉N₇O₂

Color and Shape: Solid

Molecular weight: 447.5328

Ref: IN-DA00367H